The therapeutic potential of the proteasome in leukaemia.
Many cellular processes converge on the proteasome, and its key regulatory role is increasingly being recognized. Proteasome inhibition allows the manipulation of many cellular pathways including apoptotic and cell cycle mechanisms. The proteasome inhibitor bortezomib has enhanced responses in newly diagnosed patients with myeloma and provides a new line of therapy in relapsed and refractory patients. Malignant cells are more sensitive to proteasome inhibition than normal haematopoietic cells. Proteasome inhibition enhances many conventional therapies and its role in leukaemia is promising.
McCloskey
Scott Marshall
SM
CCRCB, Queen's University of Belfast, Belfast, Northern Ireland. smccloskey@doctors.org.uk
McMullin
Mary Frances
MF
Walker
Brian
B
Irvine
Alexandra E
AE
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D002453:Cell Cycle; D002986:Clinical Trials as Topic; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D007938:Leukemia / Q000378:metabolism* / Q000628:therapy*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000378:metabolism* / Q000628:therapy*; D008495:Medical Oncology / Q000379:methods; D008954:Models, Biological; D011480:Protease Inhibitors / Q000627:therapeutic use; D046988:Proteasome Endopeptidase Complex / Q000737:chemistry / Q000378:metabolism*; D011719:Pyrazines / Q000627:therapeutic use; D012008:Recurrence
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib; D046988:Proteasome Endopeptidase Complex